Taiwan’s CancerFree Biotech Ltd develops the world’s first personalized commercial cancer cell profile
- Develops a personalized cancer profile so patients find the right medications quickly
- A marketable system grows cancer cells ex vivo with just a blood sample
- Cultivate cancer cells up to six times faster than other methods
TAIPEI, July 29, 2022 /PRNewswire/ — Taiwanese company CancerFree Biotech Ltd. developed a breakthrough for patients with stage 2 solid tumor. Stage 2 or higher patients shorten drug therapy screening process with personalized cancer profile, innovative technology to be showcased at US Bio 2022.
It is the world’s first commercial circulating tumor cell-derived organoid (CDO) culture system under its EVA Technology Platform (Ex Vivo Avatar)which, compared to other technologies currently available on the market, offers greater effectiveness, efficiency and speed.
The technology not only shortens the trial time of different therapies, but also reduces the risk of side effects for patients who have not yet found an effective drug.
As only 20ml of blood will be required, this makes the system very convenient for sampling, especially in elderly patients, or where it is difficult to obtain tissue samples. Technology makes it easier, easier, more comfortable and easier for doctors and patients to find appropriate drug treatment.
“When my elderly father was diagnosed with cancer in 2015, the process to treat it was just tedious. The lack of technology to optimize the process was frustrating to say the least.”
“Despite my background in computer science, I was determined to find a better way to make the therapy selection process easier,” said founder Po Chen.
The science behind the system
Determining the right therapies for cancer patients can be a time-consuming and expensive affair, not to mention drug resistance that can become a huge problem for patients. Additionally, collecting tissue samples from patients can be an invasive and uncomfortable experience for many.
CancerFree Biotech’s CDO system develops a patient’s personalized cancer profile (called an “avatar”) by growing their cancer cells in a lab to simulate the body’s response to a drug.
The system helps physicians perform personalized drug susceptibility testing with the patient’s tumor profile prior to treatment selection, thereby speeding up the drug selection process and reducing the risk of drug resistance.
The technology dramatically reduces the time it takes to grow almost any type of cancer cell in less than four weeks, compared to the academy’s other systems, which can take up to 24 weeks just for specific types of cancers.
“We isolate very small numbers of circulating tumor cells that enter the bloodstream from tumors in situ (on site) and grow the cells ex vivo (outside the body) using 3D scaffolds. This increases the number of cancer cells that we can work with to build a tumor avatar (tumor profile) of the patient.”, shared [Dr. Lu, the one of inventors].
The 3D scaffold mimics the bone marrow-like structure in vivo (the inside of the patient’s body) and replicates the tumorigenesis (tumor proliferation) environment for the company to test drugs.
A very effective solution
Blood samples are homogeneous and more representative than local tissue samples if the tumor shows distant metastases. This is why CancerFree Biotech’s innovative CDO system is highly efficient and successfully proliferates cancer cells ex vivo in approximately 90% of over 100 cancer types. It is also fast, as evidenced by its high effectiveness, seeing cancer cell proliferation increase 1,000 to 100,000 times in four weeks.
“They have successfully used breakthrough technology and have seen success in over 900 cancer cases. Additionally, the system can be paired with over 100 types of generic drugs, making it easier for doctors to find a drug appropriate to match the patient’s tumor profile.”, said [Dr. Chiu, the dean of TMU Hospital].
Types of cancer that can be tested include all solid tumors, such as lungs, breasts, colon, prostate, ovaries, liver, stomach, pancreas, kidneys, bladder, skin, brain, sarcomas and various other rare cancers.
Additionally, proprietary software developed by CancerFree Biotech automates drug selection, making it easy for users to find needed drugs for patients. The company was currently invested by Berkeley Skydeck and the Taiwanese Ministry of Science and Technology (MOST) sponsored them to exhibit at the international Bio convention.
The taipei office includes 13 team members, with patients from Japan and Vietnam. The original patent of the technology comes from the United States and Taiwan with exclusive license from Taipei Medical University.
Provided free of charge to pediatric patients, the system is fully marketable and the company is in its revenue stage. CancerFree Biotech hopes to cooperate with pharmaceutical companies to advance the technology.
SOURCE Biotech without cancer